Global Diabetes Devices and Drugs Market: Segmental Highlights and Table of Content (2013 2019)
Global Diabetes Devices and Drugs Market: SGLT-2 Inhibitors Segment to Expand at
Impressive 76.80% CAGR from 2013 to 2019
The global diabetes devices and drugs market will expand at a moderate CAGR of 5.90% during the
forecast period from 2013 to 2019, according to a report from Transparency Market Research
(TMR). This report is titled “Diabetes Devices and Drugs Market - Global Industry Analysis,
Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019”. In 2012, the global
diabetes devices and drugs market was worth more than US$54.0 bn and by 2019, the market is
projected to be worth US$83.0 bn.
Therapy-wise, the global diabetes devices and drugs market is segmented into insulin, non-insulin
injectable anti-diabetes drugs, and oral anti-diabetes drugs. Long-acting insulin derivatives held a
share of 42.7% in the global diabetes devices and drugs market in 2012. Among oral anti-diabetes
drugs, the SGLT-2 inhibitors segment will witness a remarkable CAGR of 76.80% during the
forecast period.
Report overview @ https://www.transparencymarketresearch.com/diabetes-devices-market.html
The global diabetes devices and drugs market is segmented into two segments, namely; diabetes
devices and diabetes drugs class. Diabetes devices segment is divided into diabetes diagnostic and
monitoring devices and insulin delivery devices. Diabetes diagnostic and monitoring devices class
is further split into analog glucose meters, test strips, lancets and lancing devices, CGM devices and
others. Insulin delivery devices class is divided into insulin pens, insulin syringes, insulin pumps
and insulin injectors. The second segment of the market, that is, drugs class is fragmented into
insulin derivatives, oral anti-diabetes drugs (OADs) and non insulin injectable anti-diabetes drugs.
Insulin derivatives are categorized on the basis of their time of action, such as, rapid-acting, shortacting, intermediate-acting, long-acting and premixed insulin derivatives. Oral anti-diabetes drugs
are divided into sulphonylureas, biguanides, meglitinides, alpha glucosidase inhibitors,
thiazolidinediones, DPP-IV inhibitors, and SGLT2 inhibitors. GLP-1 agonists represent the
injectable anti-diabetes drugs class. The report also provides in-depth analysis of pipeline diabetes
drugs.
Request A Sample Report @ https://www.transparencymarketresearch.com/sample/sample.php?
flag=S&rep_id=14
Summary of Table of Content
1.
2.
3.
4.
5.
6.
7.
8.
Introduction
Executive Summary
Disease Overview: Diabetes
Market Overview
Diabetes Devices Market, by Device Types
Global Diabetes Drugs Market, by Drug Therapy
Diabetes Devices and Drugs Market Revenue, by Geography
Competitive Landscape
Get Full Report @ https://www.transparencymarketresearch.com/checkout.php?
rep_id=14&ltype=S
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business
information reports and services. The company’s exclusive blend of quantitative forecasting and
trend analysis provides forward-looking insight for thousands of decision makers. TMR’s
experienced team of analysts, researchers, and consultants use proprietary data sources and various
tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it
always reflects the latest trends and information. With extensive research and analysis capabilities,
Transparency Market Research employs rigorous primary and secondary research techniques to
develop distinctive data sets and research material for business reports.
Contact
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Sales: [email protected]
Website: www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/